本文選題：利培酮　切入點(diǎn)：精神分裂癥　出處：《天津醫(yī)科大學(xué)》2012年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：糖代謝異常在精神分裂癥患者人群中的發(fā)病率高于普通人群,其發(fā)生機(jī)制尚有爭(zhēng)論。有研究提示高催乳素血癥可能與胰島素抵抗和糖耐量降低的發(fā)生有關(guān)。本項(xiàng)研究初步探討利培酮治療的精神分裂癥患者催乳素水平、體脂參數(shù)、胰島素敏感性之間的相關(guān)性。 方法：對(duì)符合入組標(biāo)準(zhǔn)的51例服用利培酮治療的住院精神分裂癥患者記錄年齡、利培酮的使用劑量、精神分裂癥病期,測(cè)量身高、體重、腰圍、臀圍,并檢測(cè)空腹血糖、血清催乳素及胰島素(FINS)。計(jì)算穩(wěn)態(tài)模型的胰島素抵抗指數(shù)(HOMA-IR)和QUICKI胰島素敏感性指數(shù)。依據(jù)體重指數(shù)(BMI)將患者分為正常體重組(18.5≤BMI24kg/m2)和超重組(BMI≥24kg/m2),使用Pearson相關(guān)分析分析血清催乳素和胰島素敏感性指標(biāo)的相關(guān)性,并分析胰島素敏感性指標(biāo)與體脂參數(shù)的相關(guān)性。 結(jié)果：催乳素與FINS、HOMA-IR、QUICKI胰島素敏感性指數(shù)(r=0.149,P0.05；r=0.134,P0.05；r=-0.103,P0.05)均無(wú)相關(guān)性；腰臀圍比(WHR)與FINS、HOMA-IR、 QUICKI胰島素敏感性指數(shù)均無(wú)相關(guān)性(r=0.218,P0.05；r=0.185,P0.05；r=-0.196,P0.05)；脂肪含量百分比(BF%)與FINS、HOMA-IR、QUICKI胰島素敏感性指數(shù)均無(wú)相關(guān)性(r=0.143,P0.05；r=0.125,P0.05；r=-0.246,P0.05)。體重指數(shù)(BMI)與FINS、HOMA-IR呈正相關(guān)(r=0.364,P0.01；r=0.328,P0.05)；QUICKI胰島素敏感性指數(shù)與BMI呈負(fù)相關(guān)(r=-0.427,P0.01)。正常體重組與超重組的催乳素水平無(wú)統(tǒng)計(jì)學(xué)差異(t=0.597,P0.05)。超重組FINS、HOMA-IR高于正常體重組(t=2.679,P0.05；t=2.753,P0.05),超重組QUICKI胰島素敏感性指數(shù)低于正常體重組(t=3.697,P0.01)。 結(jié)論：服用利培酮治療的精神分裂癥患者催乳素水平與胰島素抵抗無(wú)相關(guān)性；體重指數(shù)(BMI)與利培酮治療的精神分裂癥患者胰島素敏感性指標(biāo)有相關(guān)性。
[Abstract]:Objective: the incidence of abnormal glucose metabolism in patients with schizophrenia prevalence is higher than in the general population, its mechanism is still controversial. Some studies suggest that hyperprolactinemia may be associated with insulin resistance and impaired glucose tolerance was related to this study. Preliminary study of risperidone in the treatment of mental division prolactin levels in patients with body fat parameters. The correlation between insulin sensitivity.
Methods: to meet the standard set of 51 patients taking risperidone in the treatment of schizophrenia patients were recorded age, dose of risperidone, schizophrenia patients, measurement of height, weight, waist circumference, hip circumference, fasting plasma glucose, serum insulin and prolactin (FINS). Calculate the index of insulin resistance (HOMA-IR QUICKI) and insulin sensitivity index. According to body mass index (BMI) were divided into normal weight group (18.5 BMI24kg/m2) and overweight (BMI = 24kg/m2), correlation analysis of serum prolactin and insulin sensitivity index using Pearson correlation analysis, correlation analysis and insulin sensitivity index and body fat parameters.
Results: FINS, HOMA-IR, QUICKI and prolactin, insulin sensitivity index (r=0.149, P0.05; r=0.134, P0.05; r=-0.103, P0.05) had no correlation; waist hip ratio (WHR) and FINS, HOMA-IR, QUICKI and insulin sensitivity index were not correlated (r=0.218, P0.05; r= P0.05; 0.185, r=-0.196, P0.05); fat content the percentage (BF%) and FINS, HOMA-IR, QUICKI and insulin sensitivity index were not correlated (r=0.143, P0.05; r=0.125, P0.05; r=-0.246, P0.05). Body mass index (BMI) and FINS, HOMA-IR was positively correlated (r=0.364, P0.01; r=0.328, P0.05); insulin sensitivity index was negatively correlated with BMI (QUICKI r=-0.427, P0.01). No significant difference between normal weight and overweight group prolactin levels (t=0.597, P0.05). The recombinant FINS, HOMA-IR higher than the normal weight group (t=2.679, P0.05; t= 2.753, P0.05), overweight QUICKI insulin sensitivity index was lower than that of normal weight Group (t=3.697, P0.01).
Conclusion: there is no correlation between prolactin level and insulin resistance in schizophrenic patients treated with risperidone. Body mass index (BMI) is correlated with insulin sensitivity index in schizophrenic patients treated with risperidone.

【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R749.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 孫靜,張志s，

本文編號(hào)：1590463